Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Ionizing radiation emitter

DRUG CLASS:

Ionizing radiation emitter

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

CD20 positive	Follicular Lymphoma	CD20 positive	Follicular Lymphoma	rituximab + ibritumomab tiuxetan Sensitive: A1 - Approval rituximab + ibritumomab tiuxetan Sensitive : A1	rituximab + ibritumomab tiuxetan Sensitive: A1 - Approval rituximab + ibritumomab tiuxetan Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	ibritumomab tiuxetan Sensitive: A1 - Approval ibritumomab tiuxetan Sensitive : A1	ibritumomab tiuxetan Sensitive: A1 - Approval ibritumomab tiuxetan Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	ibritumomab tiuxetan Sensitive: A2 - Guideline ibritumomab tiuxetan Sensitive : A2	ibritumomab tiuxetan Sensitive: A2 - Guideline ibritumomab tiuxetan Sensitive : A2
FOLH1 expression	Prostate Cancer	FOLH1 expression	Prostate Cancer	PNT2002 Sensitive: B - Late Trials PNT2002 Sensitive : B	PNT2002 Sensitive: B - Late Trials PNT2002 Sensitive : B
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	PNT2002 Sensitive: B - Late Trials PNT2002 Sensitive : B	PNT2002 Sensitive: B - Late Trials PNT2002 Sensitive : B
FAP expression	Sarcoma	FAP expression	Sarcoma	AAA614 Sensitive: D – Preclinical AAA614 Sensitive : D	AAA614 Sensitive: D – Preclinical AAA614 Sensitive : D
FAP expression	Pancreatic Cancer	FAP expression	Pancreatic Cancer	AAA614 Sensitive: D – Preclinical AAA614 Sensitive : D	AAA614 Sensitive: D – Preclinical AAA614 Sensitive : D
ERBB3 expression	Renal Cell Carcinoma	ERBB3 expression	Renal Cell Carcinoma	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical 177Lu-satetraxetan-lilotomab Sensitive : D	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical 177Lu-satetraxetan-lilotomab Sensitive : D
ERBB3 expression	Prostate Cancer	ERBB3 expression	Prostate Cancer	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical 177Lu-satetraxetan-lilotomab Sensitive : D	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical 177Lu-satetraxetan-lilotomab Sensitive : D
ERBB3 expression	Colorectal Cancer	ERBB3 expression	Colorectal Cancer	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical 177Lu-satetraxetan-lilotomab Sensitive : D	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical 177Lu-satetraxetan-lilotomab Sensitive : D
ERBB3 expression	Ovarian Cancer	ERBB3 expression	Ovarian Cancer	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical 177Lu-satetraxetan-lilotomab Sensitive : D	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical 177Lu-satetraxetan-lilotomab Sensitive : D
CD38 positive	Multiple Myeloma	CD38 positive	Multiple Myeloma	Actinium-225 conjugated to daratumumab Sensitive: D – Preclinical Actinium-225 conjugated to daratumumab Sensitive : D	Actinium-225 conjugated to daratumumab Sensitive: D – Preclinical Actinium-225 conjugated to daratumumab Sensitive : D
CD38 positive	Burkitt Lymphoma	CD38 positive	Burkitt Lymphoma	Actinium-225 conjugated to daratumumab Sensitive: D – Preclinical Actinium-225 conjugated to daratumumab Sensitive : D	Actinium-225 conjugated to daratumumab Sensitive: D – Preclinical Actinium-225 conjugated to daratumumab Sensitive : D